A phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MEDI7247 in patients with select relapsed/refractory hematologic malignancies.

Amir T. Fathi,William B. Donnellan,Roger M. Lyons,Michael B. Maris,Tae Min Kim,Won-Seog Kim,Gary J. Schiller,Camille N. Abboud,Martha Arellano,Elizabeth H. Cull,Karen Yee,Danielle Michelle Townsley,Fujun Wang,John G. Bothos,Nai-Shun Yao,Gilles Salles

A phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MEDI7247 in patients with select relapsed/refractory hematologic malignancies.

2018

Amir T. Fathi
William B. Donnellan
Roger M. Lyons
Michael B. Maris
Tae Min Kim
Won-Seog Kim
Gary J. Schiller
Camille N. Abboud
Martha Arellano
Elizabeth H. Cull
Karen Yee
Danielle Michelle Townsley
Fujun Wang
John G. Bothos
Nai-Shun Yao
Gilles Salles

TPS2603Background: Survival outcomes in patients with relapsed/refractory multiple myeloma (MM), acute myeloid leukemia (AML), or diffuse large B-cell lymphoma (DLBCL) remains poor, and there is a ...

Keywords:

Physical therapy
Pharmacodynamics
Immunogenicity
Medicine
Tolerability
Pharmacology
Pharmacokinetics
open label
antitumor activity
in patient
Lymphoma
Oncology
Internal medicine
Pathology
Myeloid leukemia

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations